Vanda Pharmaceuticals Secures FDA Nod for BYSANTI, Expanding Psychiatric Treatment Options
Event summary
- FDA approved Vanda Pharmaceuticals' BYSANTI (milsaperidone) for treating bipolar I disorder and schizophrenia in adults.
- BYSANTI is a new chemical entity bioequivalent to iloperidone, leveraging its established safety and efficacy profile.
- Vanda anticipates commercial launch in Q3 2026, with patent exclusivity extending to 2044.
- BYSANTI is being tested as an adjunctive treatment for treatment-resistant major depressive disorder.
- This is Vanda's second new drug approval in under two months, following NEREUS™ in December 2025.
The big picture
Vanda's FDA approval for BYSANTI underscores its strategic focus on psychiatric innovation, following a similar approval for NEREUS™. The company is positioning itself as a key player in addressing unmet needs in behavioral health, with a robust pipeline and long-term patent protection. The approval comes amid growing demand for effective treatments for bipolar disorder and schizophrenia, which affect millions of Americans.
What we're watching
- Market Penetration
- Whether BYSANTI can capture significant market share in the competitive antipsychotic space.
- Pipeline Expansion
- The pace at which Vanda advances BYSANTI into additional indications, such as treatment-resistant depression.
- Commercial Execution
- How Vanda's commercial team scales to support the launch of two new drugs within months of each other.
Related topics